Skip to content
Review

Telmisartan: distinct pharmacological features, partial PPAR-γ modulation, and pleiotropic therapeutic potential.

Oct 2026 · European Journal of Pharmacology · pp. 179400 · 0 citations · 236 references
Medicine

TL;DR

Findings support the concept that telmisartan exerts diverse biological effects, positioning it as a versatile therapeutic agent in modern clinical practice with implications that extend beyond traditional RAAS inhibition.

Abstract

Telmisartan, a selective angiotensin II type 1 (AT1) receptor antagonist, is widely used in the management of hypertension by selectively blocking AT1 receptor mediated signaling, thereby attenuating the deleterious effects of excessive renin angiotensin aldosterone system (RAAS) activation without directly inhibiting ACE2, AT2 receptors, or other components of the renin angiotensin system. This results in reduced vascular resistance, decreased aldosterone secretion, and improved cardiovascular and renal protection. This review outlines the broadened therapeutic scope of telmisartan, highlighting its established pleiotropic mechanisms and emerging therapeutic applications beyond its primary antihypertensive indication. Accumulating data indicate that it influences metabolic homeostasis by enhancing insulin responsiveness and regulating lipid dynamics, suggesting potential utility in conditions associated with metabolic imbalance. In addition, telmisartan demonstrates the capacity to modulate inflammatory pathways and counteract oxidative stress, contributing to improved vascular integrity and functional stability. Compared with other ARBs, telmisartan is distinguished by its partial PPARγ agonistic activity, prolonged elimination half-life, high lipophilicity, and sustained AT1 receptor blockade, which may provide additional metabolic and vascular effects. However, these pharmacological distinctions do not consistently translate into superior clinical outcomes across all therapeutic settings, and direct comparative evidence remains limited. Emerging evidence also points toward its involvement in interconnected cellular signaling networks, extending its relevance in complex disease mechanisms. Collectively, these findings support the concept that telmisartan exerts diverse biological effects, positioning it as a versatile therapeutic agent in modern clinical practice with implications that extend beyond traditional RAAS inhibition.

View source

Similar papers

Review Open access Oct 2026

Dexamethasone-mediated modulation of the renin-angiotensin system: current insights.

Dexamethasone (DEX) exerts pleiotropic effects that extend beyond classical glucocorticoid receptor signaling and include interactions with the renin-angiotensin system (RAS). Growing evidence indicates that DEX regulates both systemic and tissue-specific RAS activity through genomic and non-genomic mechanisms, affecti...

Katarzyna J. Gajewska, Anna Wosiak, Natasza Wiertek-Płoszaj et al. · 0 citations
Review Open access Aug 2026

The Impact of Telmisartan on Inflammation and Oxidative Stress in Human Studies and Murine Models: A Narrative Review

Chronic inflammation and oxidative stress play a critical role in conditions such as atherosclerosis, metabolic syndrome, and diabetic nephropathy. Telmisartan is a unique long-acting ARB due to its dual mechanism of action. In addition to blocking the AT1R, it acts as a partial agonist for peroxisome proliferator-acti...

Ali Karbasforoushan, Saghar Samimi, Mahsa Sanatkar et al. · 0 citations
Open access Oct 2026

Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes

Piperazine-1-ium derivative 24a stands out as the first permanently charged CB1R antagonist, exhibiting nanomolar affinity and high CB1R/CB2R selectivity with a favorable physicochemical profile consistent with peripheral restriction and limited blood-brain barrier penetration.

J. Azuaje, Rubén Prieto-Díaz, Claudia Gioé-Gallo et al. · 0 citations
Review Open access Oct 2026

Sartans and Bisartans: Expanding Therapeutic Horizons Through Broad Receptor Interactions and Repurposing Potential

Angiotensin receptor blockers (ARBs), also known as sartans, are a family of highly selective angiotensin II type 1 receptor antagonists commonly prescribed to individuals with hypertension, heart failure, and chronic kidney disease. Additionally, the discovery and facile synthesis of bisartans, a novel class of ARB an...

Errikos Petsas, V. Apostolopoulos, Despoina P. Kiouri et al. · 0 citations
Review Open access Sep 2026

Aldosterone Synthase Inhibitors: Emerging Therapeutic Strategies in Resistant Hypertension

Resistant hypertension (RH) is a high-risk phenotype associated with increased cardiovascular and renal morbidity despite multidrug therapy. Dysregulation of the renin–angiotensin–aldosterone system (RAAS), particularly excess aldosterone activity, plays a central role in the pathophysiology of RH. Although conventiona...

Akshyaya Pradhan, M. Bhandari, Abhishek Singh et al. · 0 citations
Review Open access Sep 2026

GLP-1 Receptor Agonists: The Next Multifunctional Class of Drugs

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established for the management of type 2 diabetes mellitus and obesity. However, growing evidence suggests that their therapeutic effects extend beyond glycemic control and weight reduction. This review summarizes the emerging pleiotropic effects of GLP-1 R...

Shubham Marbade · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.